8F8 Stock Chart & Stats
€2.08
€0.06(6.50%)
At close: 4:00 PM EST
€2.08
€0.06(6.50%)
Day’s Range― - ―
52-Week Range€0.97 - €2.32
Previous CloseN/A
Volume0.00
Average Volume (3M)89.00
Market Cap
€89.34M
Enterprise Value€913.67
Total Cash (Recent Filing)€65.78M
Total Debt (Recent Filing)€1.07M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding53,330,242
10 Day Avg. Volume268
30 Day Avg. Volume89
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Equity BufferThe near-zero debt and a meaningful equity base provide durable financial flexibility for an early-stage biotech. This reduces short-term solvency risk and extends runway for R&D programs, lowering immediate refinancing pressure over the next several months.
Focused Lead Program With Novel MechanismA single, clearly defined lead candidate targeting inflammation through a resolution pathway is a structural asset: a differentiated mechanism can create competitive moat in inflammatory/autoimmune niches, concentrating R&D resources and regulatory focus over the medium term.
Improving Cash Burn TrajectoryA reduction in cash burn and positive TTM free cash flow growth versus the prior year signals improving operational discipline. If sustained, it lengthens funding runway and reduces near-term financing frequency, improving structural stability over months.
Bears Say
No Revenue And Persistent LossesThe absence of any product revenue and recurring large net losses make the business structurally dependent on external financing. Without commercialization or licensing wins, funding risk and value destruction remain primary long-term constraints on viability.
Sustained Negative Cash FlowMaterial and persistent negative operating/free cash flow indicate continued cash burn to fund R&D. This creates structural reliance on capital markets or partnerships, increasing dilution or financing risk and constraining strategic optionality over the next several months.
Negative Return On EquityA large negative ROE reflects that invested capital is not generating returns and shareholder value is being eroded. Over a multi-month horizon, this metric signals weak operational efficiency and elevates the bar for management to demonstrate value-creating milestones or partnerships.
SynAct Pharma AB News
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was €0.97 and its highest was €2.32 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is €89.34M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 23 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on May 27, 2026. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.043.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -€0.043 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.789%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in DE:8F8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―